---
schema_version: "secwatch.filing_event.v1"
accession: "0000313143-25-000021"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:52:28.830210+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Haemonetics approves restructuring $20M charges; targets $30M annual savings

## Summary
- Board approved market and regional alignment initiative in May 2025.
- Expected aggregate restructuring charges of ~$20M, half severance, half other exit costs.
- Savings of ~$30M annually expected by end fiscal 2027.
- Q4 and FY 2025 earnings press released issued; no specific figures available in filing.
- Charges will be cash outlays; initiative to continue through fiscal 2027.

## SEC filing metadata
- accession: 0000313143-25-000021
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000031314325000021/0000313143-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000031314325000021/hae-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313143-25-000021
- JSON: https://secwatch.observer/filing/0000313143-25-000021.json
- Plain text: https://secwatch.observer/filing/0000313143-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.